Oral Health, Orofacial Function and Oral Health Care in Patients With Parkinson's Disease Trial N/A Completed May 7, 2024
Effect of Simultaneous Dual Stimulation on Freezing of Gait in Parkinson's Disease Trial N/A Completed May 6, 2024
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives Trial N/A Unknown May 6, 2024
Promoting Physical Activity Engagement for People With Early-mid Stage Parkinson's Disease (Engage-PD) Trial Phase 1 Unknown May 2, 2024
Efficacy of Acupuncture for the Treatment of Parkinson's Disease Related Constipation Trial N/A Recruiting May 1, 2024
Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Disease Trial Phase 2 Completed April 30, 2024
A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients Trial Phase 1 Completed April 30, 2024
GentleCathâ„¢ for Men Intermittent Catheter With FeelCleanâ„¢ Technology Trial N/A Completed April 29, 2024
Effect of Virtual Reality on Freezing Phenomenon, Balance, Functional Mobility, Participation in Parkinson's Patients Trial N/A Unknown April 29, 2024
Subthalamic Nucleus Stimulation Electrode and Psychiatric Lesion Effects in Parkinson's Disease Trial N/A Completed April 28, 2024
A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients Trial Phase 1 Completed April 28, 2024
A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017 Trial Phase 1 Unknown April 28, 2024
Diaphragmatic Thickness and Pulmonary Function in Parkinson's Disease Trial N/A Completed April 25, 2024
Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease Trial Phase 4 Completed April 24, 2024
The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers. Trial Phase 1 Completed April 24, 2024
Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease Trial Phase 3 Completed April 24, 2024